Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Tongfei Wu, Hillary Millar, Dana Gaffney, Lijs Beke, Geert Mannens, Petra Vinken, Ivan Sommers et al.
Title JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models
Abstract Text Cancer Res 2018;78(13 Suppl):Abstract nr 4859


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
JNJ-64619178 JNJ64619178|JNJ 64619178 JNJ-64619178 is a PRMT5 inhibitor that binds to and inhibits the S-adenosylmethionine (SAM) and substrate-binding regions of the PRMT5/MEP50 complex, potentially reducing dimethylation of target proteins such as SMD1/3 and resulting in tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 4859).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung cancer not applicable JNJ-64619178 Preclinical - Cell line xenograft Actionable In a preclinical study, JNJ-64619178 treatment inhibited tumor growth and induced regression in cell line xenograft models of small cell and non-small cell lung carcinoma (Cancer Res 2018;78(13 Suppl):Abstract nr 4859). detail...